Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford announced today that it has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Pipette and test tubes

Through the collaboration, Oxford academics will work with Janssen scientists to develop a cellular map of genes and proteins implicated across a range of immune-mediated inflammatory disorders and characterize pharmacologically relevant therapeutic targets. The agreement was facilitated by Johnson & Johnson Innovation.

Lead Oxford investigator for the project, Professor Holm Uhlig said, 'This exciting endeavor brings together a world leading group of Janssen and Oxford scientists to form the Cartography collaboration. This project aims to create a detailed cellular map across multiple immune disorders which has the potential to advance the understanding of disease mechanisms, how to treat the right patients with the right medications, and the development of new therapies.'

Read the full story on the University of Oxford website.